China Aims to Cement Its Place at Forefront of Biomedical Innovation with New 5-Year Plan
- China released a 2026–2030 pharmaceutical plan targeting a globally leading position in biomedical research, development, and applications by 2030.
- The plan calls for China-developed first-in-class drugs to account for at least 25% of the global total, while innovative-drug growth should average at least 20% annually.
- China aims for pharmaceutical companies above the designated revenue threshold to generate at least 3.5 trillion yuan by 2030, with 50 companies exceeding 10 billion yuan in annual revenue.
- Overseas licensing deals for Chinese innovative drugs exceeded $120 billion this year.
13 Articles
13 Articles
PECHINO (XINHUA/ITALPRESS) China published yesterday a five-year plan dedicated to the pharmaceutical industry, setting targets including the world-leading maintenance of biomedical research, development and application by 2030. A move that signals the country's determination to transform pharmaceutical innovation into a strategic strength.The plan, published jointly by the Ministry of Industry and Information Technology and by nine other author…
China Daily
XinhuaChina aims to cement its place at forefront of biomedical innovation with new 5-year plan
The Asian country seeks to consolidate itself as a world power in biomedicine by 2030, with targets focused on innovation, research and development of new medicines. The program aims to raise the revenues of the main pharmaceutical companies, expand R & D investment and strengthen the presence of products in international markets.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
